• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 10-Q/A filed by iCAD Inc.

    8/14/24 5:15:29 PM ET
    $ICAD
    Medical/Dental Instruments
    Health Care
    Get the next $ICAD alert in real time by email
    true This Amendment No. 1 to Quarterly Report on Form 10-Q/A (this "Amended Report") is filed with the Securities and Exchange Commission (the "Commission") to amend the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 (the "Original Report") of iCAD, Inc., solely to correctly state the date of August 13, 2024, the date the Original Report was filed with the Commission, in three instances. FY 2024 --12-31 0000749660 0000749660 2024-01-01 2024-06-30 0000749660 2024-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     


     

    FORM 10-Q/A

    (Amendment No. 1) 

     


    (Mark One)

    ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the quarterly period ended June 30, 2024

     

    OR

     

    ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the transition period from                  to                 

     

    Commission file number 001-09341 

     


     

    iCAD, Inc.

    (Exact name of registrant as specified in its charter)

     


     

    Delaware

    02-0377419

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

       

    98 Spit Brook Road, Suite 100, Nashua, NH

    03062

    (Address of principal executive offices)

     

    (Zip Code)

     

     

    (603) 882-5200 

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name, former address and former fiscal year, if changed since last report)

     


     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    symbol(s)

     

    Name of each exchange

    on which registered

     

    Common Stock, $0.01 par value

    ICAD

    The Nasdaq Stock Market LLC

     


     

    Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirement for the past 90 days. Yes ☒ No ☐.

     

    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐.

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, an emerging growth company or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large Accelerated filer

     

    ☐

     

    Accelerated filer

     

    ☐

     

           

    Non-accelerated filer

     

    ☒

     

    Smaller reporting company

     

    ☒

     

           
       

    Emerging growth company

     

    ☐

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐.

     

    Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐ No ☒.

     

    As of the close of business on August 13, 2024, there were 26,540,030 shares outstanding of the registrant’s Common Stock, $0.01 par value.

     

     

     


    EXPLANATORY NOTE

     

    This Amendment No. 1 to Quarterly Report on Form 10-Q/A (this “Amended Report”) is filed with the Securities and Exchange Commission (the “Commission”) to amend the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 (the “Original Report”) of iCAD, Inc., solely to correctly state the date of August 13, 2024, the date the Original Report was filed with the Commission, in three instances.

      

    Exhibit

    No.

     

    Description

    104*

     

     

    Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101).

     

    * Filed herewith

     

     

     

     

    Signatures

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

       

    iCAD, Inc.

       

    (Registrant)

     

           

    Date: August 13, 2024

     

    By:

    /s/ Dana Brown

       

    Name:

    Title:

     

    Dana Brown

    Chief Executive Officer

    (Principal Executive Officer)

     

           
    Date: August 13, 2024  

    By:

    /s/ Eric Lonnqvist

       

    Name:

    Title:

     

    Eric Lonnqvist

    Chief Financial Officer

    (Principal Financial Officer)

     

     

     

     

     

    Get the next $ICAD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ICAD

    DatePrice TargetRatingAnalyst
    4/17/2025Buy → Neutral
    BTIG Research
    4/17/2025Buy → Hold
    Laidlaw
    1/18/2022Buy → Neutral
    Guggenheim
    1/5/2022$22.00 → $16.00Outperform
    Oppenheimer
    11/10/2021$22.00 → $18.00Market Outperform
    JMP Securities
    More analyst ratings

    $ICAD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy

    MindWalk Holdings Corp.™ ("MindWalk," "Company," "we" or "us") (NASDAQ:HYFT), bio-native AI company today announces the appointment of industry veteran R. Scott Areglado as Chief Financial Officer (CFO), effective October 20, 2025. "Scott's extensive experience leading financial strategy for high-growth, publicly traded healthcare and technology companies makes him an ideal addition to our executive team," said Dr. Jennifer Bath, MindWalk CEO. "His proven ability to strengthen financial systems, execute disciplined growth initiatives, and communicate effectively with the investment community will be instrumental as we scale our Bio-Native AI platform globally." Mr. Areglado brings more

    10/21/25 8:28:00 AM ET
    $BWAY
    $HYFT
    $ICAD
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    RadNet's Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of iCAD

    Acquisition contributes iCAD's commercial, technology, and regulatory capabilitiesThe acquisition positions DeepHealth with an industry-leading suite of AI-powered breast cancer image interpretation and workflow solutionsThe combination is expected to provide acceleration of AI adoption and expanded worldwide access to advanced breast cancer screening and diagnosis technologies LOS ANGELES, July 17, 2025 (GLOBE NEWSWIRE) --  RadNet, Inc. (NASDAQ:RDNT) ("RadNet"), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, announced today that it has completed the acquisition of iCAD, Inc. (NASDAQ:ICAD) ("iCAD"), a global lead

    7/17/25 9:00:00 AM ET
    $ICAD
    $RDNT
    Medical/Dental Instruments
    Health Care
    Medical Specialities

    iCAD Announces Proxy Advisory Firms ISS and Glass Lewis Recommend Stockholders Vote "FOR" Proposed Acquisition by RadNet, Inc.

    NASHUA, N.H., July 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company"), a global leader in clinically proven AI-powered cancer detection solutions, today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. ("ISS") and Glass, Lewis & Co. ("Glass Lewis") have each recommended that stockholders vote "FOR" the previously announced acquisition of the Company by RadNet, Inc. ("RadNet") at the Company's upcoming Special Meeting of Stockholders scheduled for July 14, 2025, at 9:00 a.m. ET to be held virtually at www.cstproxy.com/icad/sm2025. As previously announced, iCAD entered into a definitive merger agreement under

    7/8/25 8:00:00 AM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    $ICAD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    iCAD downgraded by BTIG Research

    BTIG Research downgraded iCAD from Buy to Neutral

    4/17/25 8:29:51 AM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    iCAD downgraded by Laidlaw

    Laidlaw downgraded iCAD from Buy to Hold

    4/17/25 8:29:51 AM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    icad downgraded by Guggenheim

    Guggenheim downgraded icad from Buy to Neutral

    1/18/22 7:19:48 AM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    $ICAD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Hricak Hedvig

    4 - ICAD INC (0000749660) (Issuer)

    7/17/25 9:02:06 PM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    Officer Go Jonathan returned 188,725 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - ICAD INC (0000749660) (Issuer)

    7/17/25 9:01:50 PM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    Director Wood Susan Alyson returned 4,134 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - ICAD INC (0000749660) (Issuer)

    7/17/25 9:01:37 PM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    $ICAD
    SEC Filings

    View All

    SEC Form 15-12G filed by iCAD Inc.

    15-12G - ICAD INC (0000749660) (Filer)

    7/28/25 4:32:12 PM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by iCAD Inc.

    EFFECT - ICAD INC (0000749660) (Filer)

    7/22/25 12:15:13 AM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by iCAD Inc.

    EFFECT - ICAD INC (0000749660) (Filer)

    7/22/25 12:15:08 AM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    $ICAD
    Leadership Updates

    Live Leadership Updates

    View All

    MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy

    MindWalk Holdings Corp.™ ("MindWalk," "Company," "we" or "us") (NASDAQ:HYFT), bio-native AI company today announces the appointment of industry veteran R. Scott Areglado as Chief Financial Officer (CFO), effective October 20, 2025. "Scott's extensive experience leading financial strategy for high-growth, publicly traded healthcare and technology companies makes him an ideal addition to our executive team," said Dr. Jennifer Bath, MindWalk CEO. "His proven ability to strengthen financial systems, execute disciplined growth initiatives, and communicate effectively with the investment community will be instrumental as we scale our Bio-Native AI platform globally." Mr. Areglado brings more

    10/21/25 8:28:00 AM ET
    $BWAY
    $HYFT
    $ICAD
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer

    NASHUA, N.H., April 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today announced the appointment of Mark Koeniguer as Chief Commercial Officer (CCO), to lead the next phase of global growth for iCAD. As CCO at iCAD, Koeniguer will assume responsibilities for revenue growth across North America and around the globe, bringing with him extensive executive experience in the medical imaging field and software as a medical device (SaMD) space. In his new role, Mark will have oversight of the commercial sales teams, partnersh

    4/8/25 10:19:01 AM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, (Dr.h.cᵐ)

    NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) a global leader in providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the appointment of Dr. Hricak to its Board of Directors, effective immediately. Dr. Hricak is a renowned radiologist and researcher with over 40 years of experience in the field. For more than 20 years, she was Chair of the Department of Radiology at Memorial Sloan Kettering Cancer Center (MSK) in New York City, a position from which she stepped down in January 2023. She continues to serve on the faculty of MSK; she holds the C

    2/27/24 9:05:00 AM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    $ICAD
    Financials

    Live finance-specific insights

    View All

    RadNet's Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of iCAD

    Acquisition contributes iCAD's commercial, technology, and regulatory capabilitiesThe acquisition positions DeepHealth with an industry-leading suite of AI-powered breast cancer image interpretation and workflow solutionsThe combination is expected to provide acceleration of AI adoption and expanded worldwide access to advanced breast cancer screening and diagnosis technologies LOS ANGELES, July 17, 2025 (GLOBE NEWSWIRE) --  RadNet, Inc. (NASDAQ:RDNT) ("RadNet"), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, announced today that it has completed the acquisition of iCAD, Inc. (NASDAQ:ICAD) ("iCAD"), a global lead

    7/17/25 9:00:00 AM ET
    $ICAD
    $RDNT
    Medical/Dental Instruments
    Health Care
    Medical Specialities

    iCAD Reports Financial Results for First Quarter Ended March 31, 2025

    NASHUA, N.H., May 13, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2025.  First Quarter 2025 Highlights (Year over Year Performance): Total ARR (Annual Recurring Revenue) was $10.7 million, up 18% year over yearQ1 total revenues of $4.9 millionGross Profit Margin of 86%92 Total deals closed in Q1, 19 of which were ProFound Cloud Dana Brown, President and CEO of iCAD commented, "We saw meaningful progress this quarter with increasing a

    5/13/25 4:01:00 PM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    RadNet, Inc. to Acquire iCAD, Inc. to Accelerate AI-Powered Early Detection and Diagnosis of Breast Cancer

    The acquisition will unite complementary leading AI-powered cancer detection and workflow solutions focused on improving the accuracy and early detection of breast cancerThe transaction is expected to add to RadNet's wholly owned subsidiary, DeepHealth, an installed base of over 1,500 healthcare provider locations across over 50 countriesWith iCAD's seasoned commercial and engineering team anticipated to join DeepHealth, the combination is expected to accelerate RadNet's growth and leadership in cancer screening and artificial intelligenceFollowing the completion of the acquisition, iCAD will be integrated into RadNet's DeepHealth portfolio of solutionsRadNet will host a conference call and

    4/15/25 4:01:37 PM ET
    $ICAD
    $RDNT
    Medical/Dental Instruments
    Health Care
    Medical Specialities

    $ICAD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by iCAD Inc. (Amendment)

    SC 13G/A - ICAD INC (0000749660) (Subject)

    2/14/24 9:00:29 AM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by iCAD Inc. (Amendment)

    SC 13G/A - ICAD INC (0000749660) (Subject)

    7/24/23 3:59:05 PM ET
    $ICAD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by iCAD Inc.

    SC 13G - ICAD INC (0000749660) (Subject)

    3/15/23 3:15:23 PM ET
    $ICAD
    Medical/Dental Instruments
    Health Care